
Trust
Sources, and how we set the windows
The short answer
Every window on this site comes from a published study, an official drug label or a clinical reference that we opened and read, and each page lists its sources. Where nothing has been measured, such as an early shed on spironolactone, finasteride or laser caps, we say so instead of filling the gap with forum lore. We also correct widely shared figures that do not match their sources.
The order of evidence we use
- Official labels and prescribing information. The minoxidil foam Drug Facts labels and the finasteride prescribing information on DailyMed define the timing the manufacturer and regulator agreed on 123.
- Randomised controlled trials and meta-analyses. For example, the finasteride trials 4, the sham-controlled laser trials 567 and meta-analyses comparing treatments 89.
- Cohort and retrospective studies. The 2025 minoxidil shedding study 10, the NYU oral minoxidil cohort 11, the 1,404-patient safety study 12 and the 400-patient adherence study 13.
- Clinical references. DermNet and the American Academy of Dermatology for definitions and general timing 1415.
- Manufacturer information, clearly labelled as such, for device directions 16.
When sources disagree, we show the range and say which source says what, rather than picking the most dramatic number.
How each timeline window was set
| Window | Where it comes from |
|---|---|
| Topical minoxidil shed, first 12 weeks | Measured every four weeks in 49 patients 10 |
| Topical minoxidil first look, 2 or 3 months | Men's and women's 5% foam labels 12 |
| Topical minoxidil checkpoint, 4 or 6 months | The same labels' "ask a doctor" points 12 |
| Minoxidil full read, 12 months | Recommendation of the 400-patient study's author 13 |
| Oral minoxidil shed, weeks 2 to 10 | Described as starting 2 to 4 weeks in and lasting 3 to 6 weeks 11 |
| Oral minoxidil and spironolactone, 6 months | DermNet guidance on assessing benefit 17 |
| Finasteride, 3, 6 and 12 months | Prescribing information and trials 34 |
| Laser cap, 16 and 26 weeks | When the trials read their results 67 |
Figures we correct
Some numbers circulate widely in hair loss content without matching their sources. Where they come up, we use the accurate version:
- "86% quit minoxidil before it works, mostly because of shedding." The real figure comes from one clinic's 400 patients: 86% had stopped, and only 12% had used it for a year or more. The main drivers were side effects, short use and perceived lack of results, not misread shedding 13.
- "78% of women with hair loss feel shame, anxiety or depression" and "peer support helped 68%." These come from a 2025 conference poster abstract pooling qualitative studies. The 68% refers to CBT and peer support groups together, not peer support alone 18.
- "Shedding always means the treatment is working." One study linked a bigger early minoxidil shed with more improvement, as a potential marker only 10, and most people do not shed noticeably 11.
What we do not do
- We do not claim to have used or tested any product ourselves. Product information comes from the maker and from published research.
- We do not invent statistics, ratings or reviews, and we do not use countdowns or fake scarcity.
- We do not cover shedding caused by life events or medicines taken for other conditions, such as childbirth, fever, crash diets or GLP-1 drugs. Those belong to Hair Experts, which specialises in triggers.
- We do not give personal medical advice. A professional who can examine your scalp is always the better source for your own case.
Keeping it current
Every source on this site was checked on 16 November 2026. When a new study changes a window, we update the page, the timeline tool and the date. If you spot an error, our contact page explains how to tell us, and our editorial policy explains how corrections are handled.
How we read different kinds of study
A randomised, sham-controlled trial, like the laser studies we cite, can show that a treatment causes a change, because a comparison group went through everything except the active treatment. A retrospective study, like the 2025 shedding study or the 400-patient adherence study, looks back at records. It is good at describing what happened to real patients and spotting patterns, but it cannot prove cause and effect. A conference abstract has not been through full peer review. We name the type of study wherever a figure appears, so a single small study is never dressed up as settled fact.
A note on the limits of studies
Studies describe groups. A window such as "within the first 12 weeks" means that is when the change was seen across the people studied. Your own shed may come earlier, later, or not at all. Many of the key studies are small or retrospective: the 2025 shedding study had 49 people 10, and the oral minoxidil cohort 115 11. We say so on each page so you can weigh them for yourself.
Sources
- Men's Rogaine 5% minoxidil foam, Drug Facts label. DailyMed, US National Library of Medicine. Open source
- Women's Rogaine 5% minoxidil foam, Drug Facts label. DailyMed, US National Library of Medicine. Open source
- PROPECIA (finasteride) tablets, prescribing information. DailyMed, US National Library of Medicine. Open source
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. Open source
- Lanzafame RJ, Blanche RR, Bodian AB, et al. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med. 2013;45(8):487-495. Open source
- Lanzafame RJ, Blanche RR, Chiacchierini RP, et al. The growth of human scalp hair in females using visible red light laser and LED sources. Lasers Surg Med. 2014;46(8):601-607. Open source
- Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss. Am J Clin Dermatol. 2014;15(2):115-127. Open source
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141. Open source
- Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses. J Dermatolog Treat. 2022;33(1):62-72. Open source
- Bi L, Kan H, Wang J, et al. Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients. J Dermatolog Treat. 2025;36(1):2480739. Open source
- Nohria A, Desai D, Sikora M, et al. Combating "dread shed": the impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD Int. 2024;15:220-224. Open source
- Vano-Galvan S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Open source
- Shadi Z. Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. Dermatol Ther (Heidelb). 2023;13(5):1157-1169. Open source
- DermNet. Telogen effluvium. Open source
- American Academy of Dermatology. Do you have hair loss or hair shedding? Open source
- Advanced Trichology. Laser cap product page (80 diodes, 650 nm, directions for use). Manufacturer information. Open source
- DermNet. Female pattern hair loss. Open source
- Psychological impact of hair loss in women: a qualitative systematic review (poster abstract P136). Br J Dermatol. 2025;193(Suppl 1). Open source
Checked 16 November 2026. See how we set the windows.